Glass House Went 'Medical-Only' to Reach the NYSE — and Kept 90% of Its Stores' Profits

Kyle Kazan spent the first part of his career enforcing the laws he now spends his days working around. Before he was the chairman and chief executive of California's largest licensed cannabis company, he was a police officer in Southern California — born in Inglewood in 1967, a beat cop who later moved into real estate and, in 2015, planted a single greenhouse in the coastal town of Carpinteria. A decade later that one greenhouse has grown into a 5.5-million-square-foot complex near Camarillo, the largest legal cannabis farm in the United States. And at 7:30 on the morning of June 17, a press release crossed the wire that did something Kazan had been building toward for years: it cut his retail stores loose.

The maneuver was quiet, lawyerly, and almost invisible to anyone not reading the filings. Glass House Brands moved its ten California dispensaries — the adult-use storefronts where ordinary customers walk in and buy recreational cannabis — into a separate company called Glass House Retail, LLC. It then sold a sliver of that company, a 10 percent voting stake, to an outside investor for roughly $2.5 million. On paper, Glass House Brands was suddenly a different kind of business: a medical-cannabis-only operator, with no recreational stores on its books.

In economic reality, almost nothing left the building. Through a separate class of non-voting units, a Glass House subsidiary kept 90 percent of the retail company's economics. The dispensaries still sell the same products to the same customers. What changed was the org chart — and the org chart was the entire point. The recreational business did not have to go away. It only had to disappear from the consolidated financial statements, because that disappearance is the price of admission to the New York Stock Exchange.

Glass House is the second major American cannabis operator in three weeks to run this play. On June 10, Trulieve Cannabis Corp. became the first U.S. plant-touching cannabis company to trade on a major American exchange, listing on the NYSE under the ticker TRLV after performing nearly the identical surgery on its own corporate structure. What looked like a one-off has, almost overnight, become a template — and the biggest operators in the industry are now restructuring themselves to walk a narrow, federally sanctioned path onto Wall Street that did not exist six months ago.

The path opened on April 23, when the Trump Justice Department reclassified medical marijuana as a Schedule III drug and, in doing so, created a registration pathway with the Drug Enforcement Administration for state-licensed medical operators. Glass House applied for that DEA registration in May. For a company that lost $29.6 million in 2025 on $181 million in revenue, access to mainstream U.S. capital matters. But Kazan is reaching for something Trulieve has not yet named out loud: the right to ship cannabis across state lines.

The deconsolidation, as the filings call it, is a small masterpiece of financial engineering. Glass House Retail now carries a three-class unit structure. A firm called NSJB Investments LLC bought 100 Class A voting units for $2.5 million — a 10 percent voting and economic interest. A Glass House subsidiary, GHB USUB, LLC, holds 900 non-voting, non-participating 'Exchangeable Units,' worth 90 percent of the economics but carrying no vote. Those units can convert into voting shares only after what the documents call the 'Stock Exchange Permissibility Date' — the day the NYSE first agrees to list companies that consolidate recreational-marijuana businesses. Until that day, on paper, Glass House does not control its own stores.

To keep the value from leaking out in the meantime, Glass House wrapped the arrangement in covenants. A management-services agreement lets a Glass House subsidiary run the retail operation for cost plus a 5 percent margin. A 'Protection Agreement,' dated June 12, limits how much debt the retail company can take on, caps distributions to the outside investor at $25,000 a month, and restricts governance changes and related-party deals. NSJB's chief executive, Jared Beilke, sits on the Glass House Retail board alongside Nicholas Sarris and Kazan himself. The separation is real enough to satisfy an accountant and thin enough to reverse the moment Washington allows it.

The blueprint came from Tallahassee. When Trulieve listed on June 10, it had already swept its adult-use operations into a separate entity, Harvest Enterprises, LLC, leaving its consolidated company with only state-licensed medical facilities — 206 dispensaries supported by 3.5 million square feet of DEA-registered production across Florida, Georgia, Pennsylvania and West Virginia. 'As the first U.S. cannabis company to list on a major U.S. exchange, we are excited for the opportunity to expand our shareholder base [and] increase liquidity,' Trulieve founder and chief executive Kim Rivers said when the listing was announced. Glass House, in the words of the trade press, was following an established script.

What sets Glass House apart from Trulieve is where it says this is all heading. In an investor deck filed the same week, the company told shareholders it had already sold its first hemp harvest and applied for an export license. It described a near future in which medical-cannabis export and interstate commerce between DEA-registered operators becomes feasible — the first serious suggestion by a major operator that rescheduling could crack open the wall that has kept American cannabis sealed inside individual state markets for a decade.

“For years, ATACH has argued that U.S. cannabis companies deserve access to major capital markets, the same access their international competitors have long enjoyed.”

— Michael Bronstein, President, American Trade Association for Cannabis and Hemp

Not everyone reads the maneuver as a clean victory. CRB Monitor, a research firm that tracks cannabis-business risk and dissected the Trulieve deal, pointed out that the adult-use operations do not actually vanish — they move into a separate company the listed entity no longer consolidates, and the parent is treated as a medical-marijuana-only operator only until the NYSE someday permits the recreational side back onto the books. The economics stay; the disclosure changes. For an investor buying TRLV, or soon a Glass House listing, the recreational business they think they are not buying is still there, 90 percent owned, waiting for a rule change.

The restructuring wave is widening regardless. Curaleaf Holdings executed a 1-for-3 reverse stock split in early June as a step toward its own uplisting. Village Farms International took a $15 million registered direct investment from U.S. institutional buyers — money its chief executive, Michael DeGiglio, said it did not need but welcomed as a signal that mainstream capital is circling the sector again for the first time in years. Each move rests on the same assumption: that the April rescheduling holds.

That assumption is not safe. The same Schedule III order that made these listings possible is now being challenged in federal court, and the DEA's own review of whether to reschedule adult-use cannabis — not just medical — remains unresolved.

A DEA administrative law judge is scheduled to begin hearings on June 29 over the broader rescheduling question. The Trump order reclassified only medical marijuana; an earlier Biden-era proposal that would have moved all cannabis to Schedule III was abandoned. Until the recreational question is settled, every operator running the Glass House play is, by the exchange's own definition, a medical company — and the recreational business that funds much of the industry sits just off the balance sheet, in a holding pattern.

1. June 29, 2026 — DEA administrative law judge opens hearings on whether to reschedule adult-use cannabis, not just medical.
2. Pending — NYSE decision on Glass House's listing application; approval would make it the second U.S. plant-touching cannabis company on the exchange.
3. Pending — federal appeals court ruling on the Republican attorneys general petition to vacate the Schedule III order.
4. Ahead — Glass House export-license approval and the first real test of interstate commerce between DEA-registered operators.

Kazan has made improbable bets before — the police officer who became a landlord who became, at 59, the largest cannabis grower in the country's largest market. The NYSE listing, if the exchange grants it, will ring up as the headline. But the bet underneath it is bigger and quieter: that the same federal government that once paid him to arrest people for marijuana will soon let a DEA-registered grower in Camarillo load a truck and ship across a state line. The org chart is already drawn for the day it does.